Black Diamond Therapeutics

Black Diamond Therapeutics

Yahoo Finance • last month

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, tod... Full story

Yahoo Finance • last month

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

Preliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastasesORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACCDose dependent and manageable AE pr... Full story

Yahoo Finance • last month

MTVA Gains Weight, CODX Takes A Shot At Ebola, EDSA To Reveal New Data, BDTX On Watch

(RTTNews) - As hedge fund tycoon George Soros once said, "It's not whether you're right or wrong that's important, but how much money you make when you're right and how much you lose when you're wrong." The following biotech stocks were am... Full story

Yahoo Finance • 5 months ago

Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Black Diamond Therapeutics, Inc. is one of the twenty best biotech stocks. TheFly reported on January 16 that Piper Sandler lowered the price target for BDTX... Full story

Yahoo Finance • 7 months ago

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to datePFS d... Full story

Yahoo Finance • 7 months ago

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target fam... Full story

Yahoo Finance • 8 months ago

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, to... Full story

Yahoo Finance • 8 months ago

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ORR and preliminary duration of treatment data for the Phase 2 trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for this quarter Cash, cash equivalents, and investments of $135.5 million as of September 30, 2025... Full story

Yahoo Finance • 11 months ago

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025Exploring partnership opportunities to advance pivotal developmen... Full story

Yahoo Finance • last year

Raymond James resumes coverage on Black Diamond stock with Outperform rating

Investing.com - Raymond James has resumed coverage on Black Diamond Therapeutics (NASDAQ:BDTX) with an Outperform rating and a price target of $11.00. Currently trading at $2.48, the stock has shown strong momentum with a 16% gain over t... Full story

Yahoo Finance • last year

ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright on strong NSCLC trial data

Investing.com - H.C. Wainwright has reiterated a Buy rating and $40.00 price target on ArriVent BioPharma (NASDAQ:AVBP) following updated results from the company’s Phase 1b FURTHER trial evaluating firmonertinib in first-line EGFR PACC-po... Full story

Yahoo Finance • last year

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS... Full story

Yahoo Finance • last year

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored “window of opportunity” trial into newly diagnosed glioblastoma patients with EGFR aberration... Full story

Yahoo Finance • last year

NAYA Biosciences Announces Nomination of New Board Members

New board reflects company’s added focus on oncology & autoimmune diseases SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing brea... Full story

Yahoo Finance • 3 years ago

With 58% ownership, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) boasts of strong institutional backing

Key Insights Significantly high institutional ownership implies Black Diamond Therapeutics' stock price is sensitive to their trading actions 53% of the business is held by the top 6 shareholders Ownership research along with analyst for... Full story

Yahoo Finance • 3 years ago

Black Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate Update

Black Diamond Therapeutics Inc (NASDAQ:BDTX) reported Q3 2023 financial results, with a net loss of $23.0 million compared to $21.7 million in the same period in 2022. The company's cash, cash equivalents, and investments stood at $144.3 m... Full story

Yahoo Finance • 3 years ago

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecula... Full story

Yahoo Finance • 3 years ago

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety or tolerability signal reported across all three active once daily doses of 100mg, 200... Full story

Yahoo Finance • 3 years ago

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients wi... Full story

Yahoo Finance • 3 years ago

Black Diamond Therapeutics Announces CEO Transition

Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company... Full story